223 results about "Enterococcus bacteria" patented technology

The invention relates to application of ten antibacterial peptides in the antimicrobial field. The ten antibacterial peptides have strong antibacterial activity on multi-drug-resistant bacteria, including but not limited to gram-negative bacteria such as escherichia coli, pseudomonas aeruginosa, acinetobacter baumannii, klebsiella pneumoniae and the like, and gram-positive bacteria such as staphylococcus aureus, enterococcus faecalis and the like. Activity research proves that any one of the ten antibacterial peptides has a remarkable effect of inhibiting, killing or preventing microbial infection. Due to the strong antibacterial property of any antibacterial peptide, the antibacterial peptide has wide application potential in the aspects of preparing antibacterial drugs, preservatives, antibacterial coatings, antibacterial fibers, antibacterial packaging materials and the like. Due to the unique property of the antibacterial peptide in the aspect of antibacterial performance, a new direction is provided for the development of efficient and reliable antibacterial agents and antibacterial technologies and products in multiple fields.

The invention belongs to the technical field of antibacterial active microorganisms, and particularly relates to a strain of diffusion carbon pad bacteria LUCF 4343-3, a bacterial agent and application of the bacterial agent in preparation of an antibacterial preparation. According to the invention, an endophytic fungus strain with remarkable antibacterial potential is successfully separated from Parmotrema, and the endophytic fungus strain is identified as diffusion carbon pad fungus LUCF 4343-3. Experiments show that an ethyl acetate extract of the strain shows a good inhibition effect on various clinical common pathogenic bacteria, including gram-positive bacteria (staphylococcus aureus and enterococcus faecalis), gram-negative bacteria (pseudomonas aeruginosa), fungi (candida albicans and candida glabrata) and the like; the discovery provides an important basis for the application of the strain in the development of novel broad-spectrum antibacterial drugs.

The invention discloses a functional probiotic composition and application thereof, and relates to the technical field of microbial engineering. Bifidobacterium longum, lactobacillus acidophilus and enterococcus faecalis are combined to serve as a microbial agent, the microbial agent and active substances of the tea leaves form a composition, then the composition is combined with prebiotics, it is ensured that viable bacteria directly reach the intestinal tract through a microencapsulation technology, and the effect of improving the immune function is achieved; tea polyphenol in the active substances of the tea leaves can serve as a carbon source of prebiotics to stimulate proliferation of the bifidobacterium longum and the lactobacillus acidophilus, so that the acid resistance and intestinal colonization capacity of the microbial inoculum are enhanced, and meanwhile, theanine in the active substances of the tea leaves, the bifidobacterium longum and the lactobacillus acidophilus synergistically promote secretion of gamma-aminobutyric acid, so that the effect of improving the intestinal colonization is achieved. And the tea polyphenol can inhibit the large intestine rod from adhering to the intestinal mucosa, and the probiotic agent secretes antibacterial peptide, so that the integrity of the intestinal barrier is maintained together.

The invention discloses a urinary system infection pathogen and drug resistance gene detection system and a kit. The detection system comprises forward and reverse primers which are respectively used for detecting escherichia coli, staphylococcus aureus, acinetobacter baumannii, klebsiella pneumoniae, enterococcus faecium, candida glabrata, proteus mirabilis, enterococcus faecalis, candida tropicalis, enterobacter cloacae, candida albicans, pseudomonas aeruginosa and streptococcus agalactiae; the forward primer and the reverse primer are respectively used for detecting the blaCTX-M gene of the extended spectrum beta-lactamase, the forward primer and the reverse primer are used for detecting the blaSHV gene of the extended spectrum beta-lactamase, and the forward primer and the reverse primer are used for detecting the blaTEM gene of the extended spectrum beta-lactamase. According to the forward and reverse primers for detecting the blaNDM gene of the extended-spectrum beta-lactamase, a detection sample is urine. According to the invention, common gram-negative bacteria, gram-positive bacteria and fungi can be detected at the same time, and the problem of missed detection of mixed infection in traditional culture is solved.

The invention discloses a compound micro-ecological preparation for aquatic products as well as a preparation method and application thereof, and belongs to the technical field of micro-ecological preparations. The microecological preparation disclosed by the invention comprises clostridium butyricum, bacillus licheniformis, enterococcus faecalis and lactobacillus plantarum. The microecological preparation is combined with concentrated cottonseed protein for use, can replace fish meal, is added into feed, can remarkably improve the immunocompetence, oxidation resistance and digestive enzyme activity of animals, and can improve the relative abundance of beneficial bacteria in intestinal tracts, inhibit the growth of pathogenic bacteria and regulate the microecological balance of the intestinal tracts after entering the intestinal tracts of the animals. According to the invention, aerobic bacteria and anaerobic bacteria are cooperatively used, oxygen in the surrounding environment is greatly consumed by bacillus licheniformis and enterococcus faecalis, the proliferation of beneficial bacteria such as clostridium butyricum and lactobacillus plantarum is promoted, and the probiotic effect is fully played.

The invention relates to the technical field of microorganisms, in particular to enterococcus faecalis EF-1 capable of reducing blood lipid, a microbial preparation and application of the enterococcus faecalis EF-1. The enterococcus faecalis EF-1 is preserved in the China General Microbiological Culture Collection Center (CGMCC) on September 27, 2024, and the preservation number is CGMCC No.32097. The enterococcus faecalis EF-1 is named as enterococcus faecalis EF-1. The enterococcus faecalis EF-1 has the functions of: (1) relieving the weight increase speed of animals, reducing body weight gain, and preventing, relieving or treating obesity; (2) the contents of triglyceride, cholesterol and low-density lipoprotein cholesterol in liver and serum are reduced; (3) the liver function is protected, and the contents of ALT and AST in serum and liver are reduced; (4) liver lipid deposition and lesion are relieved; (5) relieving adipose tissue hypertrophy; (6) preventing, relieving or treating metabolic syndrome; (7) reducing blood sugar, improving insulin resistance and relieving diabetes mellitus; 8, increasing the content of short-chain fatty acid; and (9) regulating intestinal flora.

The present invention provides a type of supramolecular hydrogel compound formed by self-assembly of effective ingredients of Macleaya cordata powder and flavonoid active molecules, a structure, a preparation method and an application. The supramolecular hydrogel compound has excellent selective antibacterial ability. While selectively killing pathogenic bacteria such as Staphylococcus aureus, it does not affect the activity of probiotics such as Bacillus subtilis and Enterococcus faecium in the intestine; it is particularly sensitive to methicillin-resistant Staphylococcus aureus (MRSA); it also has good anti-inflammatory effects and promotes wound healing. Among them, the natural supramolecular hydrogel formed by the self-assembly of effective ingredients of Macleaya cordata powder and flavonoid active molecules has a uniform morphology, good dispersion and stability, forms a gel without the need for excipients, and has the value of being developed into a carrier-free drug delivery preparation. The general structural formula of the compound is shown below:

The invention discloses a compound microbial agent for preventing and treating fusarium wilt of cotton and application of the compound microbial agent, and belongs to the technical field of biological prevention and treatment of plant diseases. The prepared compound microbial agent is obtained by mixed culture of clostridium butyricum JBH-BD1 fermentation centrifugate, enterococcus faecium JBHBIO-BSC1, glucose and bacillus subtilis JBH-BK8, the preparation method is simple, and industrialized production, popularization and application are facilitated. The compound microbial agent has an obvious inhibition effect on cotton fusarium wilt caused by fusarium oxysporum, and the bacteriostasis rate reaches 66.7%. The harm of the cotton fusarium wilt to cotton is effectively reduced by utilizing a biotechnology, meanwhile, compared with a chemical agent, the problems of environmental pollution and the like are effectively avoided, and the application prospect is very wide.

The invention discloses a composition containing three lactic acid bacteria strains and an application of the composition in prevention of EHP (Ethylene Hypothionyl Phthalate) of white shrimps. The three lactic acid bacteria strains provided by the invention are respectively enterococcus faecium EF08, lactobacillus plantarum LP28 and lactobacillus acidophilus LA1063. The mass ratio of the enterococcus faecium EF08 to the lactobacillus plantarum LP28 to the lactobacillus acidophilus LA1063 is 1 to 3 to 0.01. Experiments show that the P1 and P2 combined probiotic strain has the application of preventing and reducing EHP disease infection of the white shrimps. Therefore, the composition disclosed by the invention can be used for preparing a medicine for preventing microsporidia EHP infection.

The invention belongs to the technical field of food microorganisms, and particularly relates to an enterococcus lactis NSK220 strain, a microbial agent and application of the enterococcus lactis NSK220 strain. The invention provides the enterococcus faecium NSK220, the clearance rate of the enterococcus faecium NSK220 on DPPH is very high, the serum SOD enzyme activity can be improved by supplementing the strain NSK220 in diet, and it is indicated that the oxidation resistance of the strain NSK220 is high. Meanwhile, the enterococcus faecium NSK220 has relatively strong self-cohesion and surface hydrophobicity, which indicates that the strain has strong colonization ability and is beneficial to long-term play of probiotic functions in intestinal tracts; the strain NSK220 can also improve the feed intake and kidney function of animals, and is beneficial to the growth and body health of the animals. The enterococcus faecium NSK220 has an inhibition effect on escherichia coli, staphylococcus aureus, salmonella, pseudomonas aeruginosa and listeria monocytogenes.

The invention discloses enterococcus faecium capable of degrading three mycotoxins at the same time and application of the enterococcus faecium, and belongs to the technical field of microorganisms. The enterococcus faecium JBHBIO-BSC1 disclosed by the invention is preserved in the China Center for Type Culture Collection, and the preservation number of the enterococcus faecium JBHBIO-BSC1 is CCTCC (China Center for Type Culture Collection) NO: M 20241918. The enterococcus faecium disclosed by the invention has the most remarkable characteristic that the enterococcus faecium has an obvious degradation effect on the aflatoxin, the vomitoxin and the zearalenone, and the degradation rates of the aflatoxin, the vomitoxin and the zearalenone can respectively reach 74.67%, 85.83% and 82.12%. The enterococcus faecium disclosed by the invention is natural, safe, acid-resistant, alkali-resistant and high-temperature-resistant, and has relatively strong organic acid production capacity. In addition, the strain has an obvious inhibition effect on escherichia coli, salmonella and staphylococcus aureus, and is expected to be applied to the fields of food processing and microbial pharmacy.

A strain of Enterococcus faecalis, a composite bacterial agent, and application thereof, which relates to the field of microbiology. The Enterococcus faecalis strain was deposited on Oct. 13, 2022, at the Guangdong Microbial Culture Collection Center (GDMCC) with the deposit number GDMCC No. 62869. Both the Enterococcus faecalis strain and the composite bacterial agent can effectively treat intestinal disorders and inflammatory bowel disease in felines and can be used in the preparation of related pharmaceuticals.

The invention discloses a wide-spectrum bacteriophage EFH2 capable of eliminating enterococcus faecalis suffering from humans and animals, and relates to the technical field of biology. The wide-spectrum bacteriophage is preserved in the China Center for Type Culture Collection on September 26, 2024, and the preservation number of the wide-spectrum bacteriophage is CCTCC NO: M 20242087. The wide-spectrum bacteriophage EFH2 is a newly found bacteriophage, has good tolerance under the conditions that the pH is 3-9 and the temperature is 4-60 DEG C, and has the titer as high as 2.31 * 10 < 8 > PFU / mL after being cultured for 8 hours under the condition that the MOI is 0.01. The wide-spectrum bacteriophage EFH2 is wide in antibacterial spectrum, short in incubation period, high in outbreak amount, capable of rapidly killing host bacteria, small in toxic and side effect, high in safety, wide in temperature and acid-base tolerance range, good in hydrophilicity and capable of well killing and disinfecting animals infected with multi-drug-resistant enterococcus and environments and food polluted by enterococcus.

The invention discloses an enterococcus faecalis bacteriophage and application thereof, and relates to the field of bioengineering, on the basis that E. faecalis YN772 is obtained through separation, E. faecalis YN772 is taken as host bacteria to be co-cultured with stomatological sewage which is not subjected to chlorine treatment, enterococcus faecalis lytic bacteriophage PEf772 is separated, the bacteriophage is preserved in China Center for Type Culture Collection (CCTCC), the preservation number is CCTCC NO: M 20241844, the preservation date is August 26, 2024, the preservation number is CCTCC NO: M 20241844, and the preservation number is CCTCC NO: M 20241844. According to the research on physiological characteristics, the phage PEf772 belongs to a tail phage and a myelocaudaceae phage, the infection temperature range is 20-42 DEG C, the optimum temperature is 37 DEG C, and the phage PEf772 has high-temperature tolerance and has activity when the pH value is 3-12. In addition, the bacteriophage PEf772 not only can efficiently and continuously remove an E.faecalis YN772 biological membrane, but also can effectively inhibit the growth of the E.faecalis YN772, and a new thought and a potential treatment strategy are provided for clinically treating the refractory periapical periodontitis caused by enterococcus faecalis.

The invention discloses a cytochalasin compound with wide antibacterial activity as well as a preparation method and application thereof. According to the present invention, the cytochalasin polymer is obtained by separation from the fermentation product derived from the Aspergillus izzukae (Aspergillus izzukae), such that the cytochalasin polymer can be obtained, the preservation number of the Aspergillus izzukae PJ03-11 is CGMCC (China General Microbiological Culture Collection Center) No.40601, and the preservation number of the Aspergillus izzukae PJ03-11 is CGMCC No.40601. The compound has a structure of a cytochalasin mother nucleus and an epiccine mother nucleus, and shows good activity in the aspects of inhibiting or killing staphylococcus aureus, methicillin-resistant staphylococcus aureus, multidrug-resistant staphylococcus aureus, streptococcus pneumoniae, staphylococcus epidermidis and vancomycin-resistant enterococcus faecalis; the compound can be used for preparing novel agricultural or medical antibacterial drugs.

The invention discloses preparation and application of a hand mycin derivative with gram-positive bacterium activity resistance, and belongs to the technical field of medicine preparation. According to the present invention, the ctd gene cluster is subjected to heterologous expression in the strain Streptomyces lividans TK64, such that the obtained hand mycin derivatives Carpatamide N and Carpatamide O show excellent biological activity on the gram-positive bacteria; the MIC (minimal inhibitory concentration) values of the Carpamide N and the Carpamide O on streptococcus faecium and enterococcus faecium are 4 mu g / mL and 1 mu g / mL respectively; the MIC (minimal inhibitory concentration) values for staphylococcus aureus and bacillus subtilis are respectively 0.25 mu g / mL and 0.125 mu g / mL, the MIC values for MRSA (Methicillin-Resistant Staphylococcus Aureus) are respectively 1 mu g / mL and 0.5 mu g / mL, and the Gram-positive bacterium resisting activity of the compound is equivalent to or better than that of vancomycin.

According to the invention, the traditional fermented koumiss in Xinjiang is collected, two novel multifunctional probiotic strains, namely, the lactobacillus plantarum SR6 GDMCC NO.66817 strain and the enterococcus faecalis SM5 GDMCC NO.66816 strain with good compatibility are separated and screened out, and the two strains have the characteristics of reducing blood fat, reducing cholesterol, removing triglyceride, resisting oxidation and antagonizing pathogenic bacteria, and have the characteristics of good cholate and gastrointestinal tract tolerance, high survival rate and good safety. The growth characteristics and compatibility of the two strains are improved; the inhibition rate of cholesterol esterase and pancreatic lipase; the method comprises the following steps: evaluating the triglyceride removal rate, antioxidant activity, pathogenic bacterium resistance, artificially simulated gastrointestinal fluid tolerance, strain drug resistance and safety, compounding lactobacillus plantarum SR6 and enterococcus faecalis SM5 strains according to a ratio of 1: 1 to prepare a freeze-dried bacterial agent, and keeping good survival rate (pgt; 0.05) and functional characteristics, the strain can be used as a functional direct vat set starter and is directly applied to production of fermented dairy products, and the biological activity of food is improved.

The invention discloses an enterococcus faecium XL, and the preservation number of the enterococcus faecium XL is CGMCC (China General Microbiological Culture Collection Center) No. 28133. The enterococcus faecium XL and the application thereof have the following beneficial effects: 1, the enterococcus faecium XL provided by the invention can grow and metabolize under an oil reservoir condition to generate lactic acid organic acid, dissolve carbonate in a rock stratum, increase the permeability of the rock stratum, degrade heavy components in crude oil, relieve crude oil blockage in an oil layer, increase the liquid amount and improve the oil reservoir quality; the oil recovery rate is improved; 2, the enterococcus faecium XL is applied to microorganism single-well throughput, the average single-well oil increasing amount is greater than 400 tons, and the validity period is more than 200 days; and 3, the enterococcus faecium XL is applied to microbial oil displacement, the average daily oil increase of a well group is more than 5 tons, and the water content drop amplitude is more than 5%.

The invention relates to the technical field of medicines, and particularly discloses application of a Xinjiang medicine mulberry extract in preparation of a medicine for treating or preventing periapical periodontitis, which is technically characterized in that the Xinjiang medicine mulberry extract is found and proved to have a remarkable inhibition effect on periapical periodontitis key pathogenic bacterium enterococcus faecalis for the first time, the minimum inhibitory concentration (MIC) is 0.604 mg / mL, and the Xinjiang medicine mulberry extract has a remarkable inhibition effect on the periapical periodontitis key pathogenic bacterium enterococcus faecalis. The minimum bactericidal concentration (MBC) is 1.875 mg / mL, and a biological membrane can be effectively inhibited and removed; in-vivo experiments of a rat periapical periodontitis model prove that the extract can remarkably reduce the number of bacteria in root canals and relieve periapical bone destruction, the curative effect is equivalent to that of calcium hydroxide, and the extract is non-toxic to main organs and high in biocompatibility. The invention provides a new candidate and a clear technical scheme for developing an efficient and low-toxicity natural plant source root canal disinfectant.

The invention relates to a biomarker for individual recognition and application thereof, and relates to the technical field of biology. The biomarker comprises at least one of the following microorganisms: propionibacterium acnes, staphylococcus epidermidis, marine paracoccus, streptococcus, rhodococcus fence celebrating, staphylococcus, pseudomonas, streptococcus sanguineus, achromobacter xylosoxidans, acinetobacter calcoaceticus, acinetobacter johnsonii, staphylococcus lentus, pseudomonas toralaris and brevundimonas vesicularis. Or enterococcus faecium. The biomarker can provide analysis with higher resolution in the aspect of differential strain information, has a better distinguishing effect, higher accuracy and sensitivity on individual recognition, and can be used as a new technical means for supplementing forensic individual recognition.

A general formula for lysins based on which the activity and functionality are further screened and 24 lysins are identified and further investigated, nine of which are characterized. These lysins exhibit potent bactericidal activity, capable of lysing multiple species of Staphylococcus, Streptococcus, and / or Enterococcus; demonstrate robust environmental resistance and stability, retaining activity under varying temperatures, NaCl concentrations, pH levels, and in immune serum; and effectively treat localized and systemic infections. These lysins and their variants are promising as antimicrobial agents for eradicating bacteria, preventing bacterial infections, or treating bacterial infections (caused by genera Staphylococcus, Streptococcus, and / or Enterococcus).

The invention provides an application of GSK2018682 in preparation of a medicine for resisting gram-positive bacterial infection, and the GSK2018682 has a CAS number of 1034688-30-6. The invention also provides an application of the GSK2018682 in preparation of a medicine for resisting gram-positive bacterial infection. According to the technical scheme, the novel medical application of the GSK2018682 is disclosed, and the GSK2018682 has good antibacterial activity and anti-biofilm activity on various gram-positive bacteria and can inhibit growth of staphylococcus aureus, staphylococcus epidermidis, enterococcus faecalis, enterococcus faecium and the like and formation of biofilms.

The invention provides an enterococcus faecium probiotic-prebiotics composite tablet and a preparation method thereof, and belongs to the technical field of microbial preparations. The tablet is prepared by taking enterococcus faecium (preservation number: CGMCC NO.33919) as a core active component, matching prebiotics adapted to the intestinal tracts of old people, a high-stability protective agent and mild auxiliary materials through a specific process. The tablet can efficiently adjust the intestinal flora structure of the old people, inhibit the proliferation of harmful bacteria in the intestinal tract and enhance the intestinal barrier function of the old people, so that the functional diarrhea and antibiotic-related diarrhea of the old people are relieved, and the tablet is moderate in hardness, easy to swallow, free of intestinal irritation and high in normal-temperature storage stability; the problems that an existing intestinal preparation is poor in adaptability to intestinal tracts of old people, strain activity is prone to inactivation, and swallowing is difficult are solved.

The invention discloses an enterococcus faecalis bacteriophage vBEfaPFA2, a bacteriophage composition and application of the enterococcus faecalis bacteriophage vBEfaPFA2, the enterococcus faecalis bacteriophage vBEfaPFA2 has a specific lysis effect on enterococcus faecalis and also has a cross-species lysis effect on salmonella, the acid-base adaptability of the bacteriophage is high, and the bacteriophage vBEfaPFA2 and the bacteriophage composition can be used for preparing the enterococcus faecalis bacteriophage The enterococcus faecalis bacteriophage can be used as an active component to be prepared into the bacteriophage composition or the bacteriophage pharmaceutical preparation, the bacteriophage composition or the bacteriophage pharmaceutical preparation is applied to preparation of a medicine or a bacteriostatic agent for preventing and treating enterococcus faecalis and salmonella infection, the enterococcus faecalis bacteriophage and the bacteriophage composition are safe to use, high in yield and easy to industrially produce, and due to the cross-species lysis performance, the bacteriophage can be The method has the advantages of wide splitting spectrum, wide application range and good application prospect.

The invention discloses specific molecular targets for simultaneously detecting important pathogenic species in enterococcus, a kit and a detection method thereof, the specific molecular targets are respectively an enterococcus specific identification target rmC and three enterococcus species specific targets E6A31RS02140, FHO10RS03365 and EH19712165, then specific primer pairs are respectively designed for the four specific molecular targets, and the specific primer pairs are respectively used for detecting the important pathogenic species in the enterococcus. A multiplex PCR detection system is constructed, whether a sample containing multiple pathogenic species genome DNAs contains enterococcus strains or not can be rapidly and accurately detected and identified, whether the enterococcus strains are enterococcus faecium, enterococcus faecalis and enterococcus avialis or not can be determined, the detection cost is reduced, and the detection efficiency is improved.

The invention discloses a specific molecular sequence and a method for rapidly detecting enterococcus hirai by using the specific molecular sequence. The base sequence of the specific molecular sequence is as shown in SEQ ID No.1-SEQ ID No.26. The invention further discloses a method for rapidly detecting enterococcus hirai by using the specific molecular sequence. The detection method comprises the following steps: designing a specific amplification primer pair according to any one molecular sequence in base sequences SEQ ID NO.1-SEQ ID NO.26; extracting DNA of a sample, and amplifying by a PCR method; and detecting an amplification product by gel electrophoresis, if a corresponding single amplification band appears in an electrophoresis result, judging that the sample contains the target bacteria, otherwise, judging that the sample does not contain the target bacteria. The detection method has the advantages of short detection time, low cost, simplicity in operation, high specificity and the like, can detect the enterococcus hillatus without biochemical identification, and is more practical.

The invention provides an antibacterial peptide RB3 and application thereof. The amino acid sequence of the antibacterial peptide RB3 is as shown in SEQ ID NO: 1. The antibacterial peptide RB3 has remarkable antibacterial activity on five endometritis pathogenic bacteria, namely, E. coli, K. pneumoniae, P. mirabilis, P. aeruginosa and E. faecium, can be used for inhibiting the growth and proliferation of the endometritis pathogenic bacteria and maintaining a normal flora structure and an immune microenvironment of endometrium, and can be used for preparing the antibacterial peptide RB3. The antibacterial peptide RB3 has the advantages that the antibacterial peptide RB3 has obvious antibacterial activity on the five endometritis pathogenic bacteria, namely, E. coli, K. pneumoniae, P. mirabilis, P. aeruginosa, P. mirabilis, P. aeruginosa and E. faecium; according to the present invention, the antibacterial peptide RB3 can be directly obtained through solid-phase synthesis, such that the effective prevention and treatment of endometritis can be achieved, the important significance on the prevention and the clinical treatment of endometritis can be provided, and the antibacterial peptide RB3 can be directly obtained through solid-phase synthesis so as to easily achieve the large-scale preparation and the clinical large-scale application of the antibacterial peptide RB3.

The invention provides a beta-diketoamide compound and application thereof in preparation of a gram infection resistant drug, the structural formula of the beta-diketoamide compound is as shown in formula (1), in the formula (1), R1 is H or halogen; r2 is nitro, alkyl, halogen or methoxyl. The beta-diketoamide compound disclosed by the invention comprises gram-positive bacteria such as staphylococcus aureus, enterococcus faecalis, enterococcus faecium and staphylococcus epidermidis and other clinical isolates, and shows antibacterial activity; after being combined with polymyxin, the compound has synergistic bacteriostatic activity on gram-negative bacteria such as acinetobacter baumannii, klebsiella pneumoniae, escherichia coli and pseudomonas aeruginosa, and can remove biofilms formed by staphylococcus aureus and enterococcus faecalis.

The use of a probiotic, particularly the Enterococcus faecium strain NCIMB 10415 which is named SF68® as probiotic active ingredient, in combination with butyric acid or a salt thereof to increase the enterocyte's health and consequently the wellness of pets and livestock is described.

The invention discloses a glycosyl hydrolase derived from intestinal bacteria and application of the glycosyl hydrolase. A glycosyl hydrolase gene for catalyzing trillioside to be hydrolyzed into diosgenin is cloned from intestinal microorganism enterococcus faecalis for the first time, and protein coded by the glycosyl hydrolase gene is identified as multifunctional glycosyl hydrolase; the diosgenin can be catalyzed to generate diosgenin, and the hydrolysis of other saponins such as steroid saponin and C3, C6 and C21 glycosyl of ginsenoside can be catalyzed, so that a basis is provided for the biological enzymolysis of the diosgenin and other saponins or sapogenin. Meanwhile, biological enzymolysis of the diosgenin makes up for the defects of high production cost, serious environmental pollution and the like of a traditional acid hydrolysis method, and the diosgenin has a great application prospect.